S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model

Canerpaturev (C-REV) is a highly attenuated, replication-competent, mutant strain of oncolytic herpes simplex virus type 1 that may be an effective new cancer treatment option. S-1, an oral formulation containing the 5-fluorouracil (5-FU) prodrug tegafur and the two enzyme modulators gimeracil and o...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyajima, Noriyuki, Ragab Eissa, Ibrahim, Abdelmoneim, Mohamed, Naoe, Yoshinori, Ichinose, Toru, Matsumura, Shigeru, Bustos-Villalobos, Itzel, Mukoyama, Nobuaki, Morimoto, Daishi, Shibata, Masahiro, Takeuchi, Dai, Tsunoda, Nobuyuki, Kikumori, Toyone, Tanaka, Maki, Kodera, Yasuhiro, Kasuya, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nagoya University 2021
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648537/
https://www.ncbi.nlm.nih.gov/pubmed/34916713
http://dx.doi.org/10.18999/nagjms.83.4.683

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648537/
https://www.ncbi.nlm.nih.gov/pubmed/34916713
http://dx.doi.org/10.18999/nagjms.83.4.683

Ejemplares similares